KEYNOTE-B21: a missed opportunity or a turning point in adjuvant immunotherapy for dMMR endometrial cancer?

Ann Oncol. 2024 Nov;35(11):925-927. doi: 10.1016/j.annonc.2024.09.006.

Authors

D Lorusso¹, G Fucà²

Affiliations

¹ Unit of Gynecologic Oncology, IRCCS Humanitas Research Hospital, Rozzano, Milan; Department of Biomedical Sciences, Humanitas University, Pieve Emanuele, Milan, Italy. Electronic address: [email protected].
² Unit of Gynecologic Oncology, IRCCS Humanitas Research Hospital, Rozzano, Milan.

PMID: 39461745
DOI: 10.1016/j.annonc.2024.09.006

No abstract available

Publication types

Editorial